MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Repare Therapeutics
RPTX
|
+$76.7M |
| 2 |
ADC Therapeutics
ADCT
|
+$20.5M |
| 3 |
Merus
MRUS
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CytomX Therapeutics
CTMX
|
+$6.56M |
| 2 |
Viracta Therapeutics
VIRX
|
+$1.17M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.87% |
| 2 | Miscellaneous | 11.13% |
Similar funds
MPM BioImpact's Q2 2020 Portfolio in Review
As of Q2 2020, MPM BioImpact held 13 positions worth $376M, up 130% from $164M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
MPM BioImpact deployed $116M of net new capital in Q2 2020, opening 3 new positions and adding to 1 existing holding. Its largest new stake was Repare Therapeutics: 2,388,337 shares worth $74.1M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 94% a quarter earlier, followed by Miscellaneous.
On the sell side, the most notable exit was CytomX Therapeutics, an estimated $6.56M sold.
- MPM BioImpact's largest Q2 2020 buy was Repare Therapeutics: 2,388,337 shares worth $74.1M.
- MPM BioImpact fully exited CytomX Therapeutics in Q2 2020, selling an estimated $6.56M.
- MPM BioImpact's ten largest holdings make up 100% of its $376M portfolio in Q2 2020.
- MPM BioImpact opened 3 new positions and closed 2 in Q2 2020.
- MPM BioImpact's portfolio value rose 130% quarter-over-quarter to $376M.
Based on MPM BioImpact's 13F filing for Q2 2020, filed 12 Aug 2020.